Use of Cytoplasmic 5'nucleotidase for Differentiating Malignant From Benign Monoclonal Gammopathies.

Journal of Clinical Pathology - United Kingdom
doi 10.1136/jcp.43.11.891
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Use of Leucocyte Alkaline Phosphatase (LAP) Score in Differentiating Malignant From Benign Paraproteinaemias.

Journal of Clinical Pathology
MedicineForensic MedicinePathology
1991English

Differentiating Benign From Malignant Cervical Lymph Nodes With Sonoelastography

International Journal of Medical Imaging
2017English

Value of Diffusion-Weighted Imaging in Differentiating Benign From Malignant Breast Lesions

Breast Cancer Research
Cancer ResearchOncology
2009English

Progression of Paralysis Is the Most Useful Factor for Differentiating Malignant From Benign Intramedullary Tumors

Spinal Cord
MedicineNeurologyRehabilitation
2012English

Application Values of 99mTc‑methoxyisobutylisonitrile Imaging for Differentiating Benign and Malignant Thymic Masses

Oncology Letters
Cancer ResearchOncology
2017English

Monoclonal Gammopathies and Kidney Disease

Clinical Journal of the American Society of Nephrology
EpidemiologyNephrologyCritical CareTransplantationIntensive Care Medicine
2018English

Urinary Neopterin in Monoclonal Gammopathies

Pteridines
BiochemistryMolecular MedicineClinical Biochemistry
1990English

5'Nucleotidase From Yeast, Having Special Affinity for 5'-Amp

Agricultural and Biological Chemistry
1965English

Role of 18F FDG PET in Differentiating Benign and Malignant Primary Bone Tumors

Bangladesh Journal of Nuclear Medicine
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy